Design and delivery of non-parenteral vaccines

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 4, 1998, Pages 257-285

  Nugent, J ^a   Li Wan Po, A ^b   Scott, E M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE; LIPOSOME; NANOPARTICLE; VACCINE; VIRUS VECTOR;

ANTIGEN EXPRESSION; BACTERIUM; DRUG DELIVERY SYSTEM; DRUG DESIGN; GENE FUSION; HOST CELL; IMMUNE RESPONSE; MUCOSA; REVIEW;

ANIMALS; ANTIGENS; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULINS; T-LYMPHOCYTES; VACCINES; VEHICLES;

EID: 0031753113     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (216)

1. BNF. (1996) British National Formulary. British Medical Association. The Pharmaceutical Press, London.
2. O'Hagan DT, Illum L. (1940) Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. CRC Critical Review Therapeutic Drug Carrier Systems, 7, 35-97.
3. Gilligan CA, Li Wan Po A. (1991) Oral Enteric Vaccines-Clinical Trials. Journal of Clinical Pharmacy and Therapeutics, 16, 309-335.
4. Mestecky J. (1987) The Common Mucosal Immune System and current strategies for the induction of immune responses in external secretions. Journal of Clinical Immunology, 7, 265-276.
5. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. (1992) The mucosal immune system: from fundamental concepts to vaccine development. Vaccine, 10, 75-88.
6. Naz RK, Sacco A, Singh O, Pal R, Talwar CP. (1995) Development of contraceptive vaccines for humans using antigens derived from gametes (spermatozoa and zona-pellucida) and hormones (human chorionic-gonadotropin) - current status. Human Reproduction Update, 1, 1-18.
7. Szewczuk MR, Campbell RJ, Jung LK. (1981) Lack of age-associated immune dysfunction in mucosal-associated lymph nodes. Journal of Immunology, 126, 2200-2204.
8. McGhee JR, Kiyono H. (1993) New perspectives in vaccine development: mucosal immunity to infections. Infectious Agents and Disease, 2, 55-73.
9. McGhee JR, Mestscky J. (1990) In defence of mucosal surfaces. Infectious Disease Clinics North America, 4, 315-341.
10. McDermott MR, Bienenstock J. (1979) Evidence for a common mucosal immunologic system. 1. Migration of B lymphocytes into intestinal, respiratory and genital tissues. Journal of Immunology, 122, 1892-1898.
11. Li Wan Po A, Rogers E, Shepphard M, Scott E. (1995) Delivery systems for non-parenteral vaccines. Advances in Drug Delivery Reviews, 18, 101-109.
12. Lintermans P, Degreve H. (1995) Live bacterial vectors for mucosal immunization. Advances in Drug Delivery Reviews, 18, 73-89.
13. Bienenstock J, Befus AD. (1980) Review. Mucosal Immunology. Immunology, 41, 249-270.
14. Gilligan CA, Li Wan Po A. (1991a) Oral Vaccines. Design and Delivery. International Journal of Pharmacy, 75, 1-24.
15. Lavelle EC, Sharif S, Thomas NW, Holland J, Davis SS. (1995) The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Advances in Drug Delivery Reviews, 18, 5-22.
16. Reudl C, Wolf H. (1995) Features of Oral Immunization. International Archives of Allergy and Immunology, 108, 334-339.
17. Kuper CF, Koornstra PJ, Hameleers DHM, et al. (1992) The role of nasopharyngeal lymphoid tissue. Immunology Today, 13, 219-224.
18. Mestecky J, Abraham R, Ogra PL. (1994) Common mucosal immune system and strategies for the development of vaccines effective at the mucosal surfaces. In Ogra, P.L, Mestecky, J, Lamm, ME et al., eds. Handbook of Mucosal Immunology. Academic Press, London, 357-372.
19. Nedrud JG, Liang X, Hague N, Lamm ME. (1987) Combined oral/nasal immunization protects mice from Sendai virus infection. Journal of Immunology, 139, 3484-3492.
20. Liang X, Lamm ME, Nedrud JG. (1988) Oral administration of cholera toxin-sendai virus conjugate potentiates gut and respiratory immunity against sendai virus. Journal of Immunology, 141, 1495-1501.
21. Wu HY, Russell MW. (1993) Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin-b subunit. Infectious Immunology, 61, 314-322.
22. Hajishengallis G, Hollingshead SK, Koga T, Russel MW. (1995) Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunit. Journal of Immunology, 154, 4322-4332.
23. Hopkins S, Kraehenbuhl JP, Schodel F, et al. (1995) A recombinant Salmonella-typhimurium vaccine induces local immunity by four different routes of immunization. Infectious Immunology, 63, 3279-3286.
24. Hensel A, van Leengoed LAMG, Szostak M, Windt H, Weissenbock H, Lubitz W. (1996) Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. Journal of Biotechnology, 44, 171-181.
25. Sullivan DA. (1994) Ocular mucosal immunity. In Ogra, PL, ed. Handbook of Mucosal Immunology. Academic Press, London, 569-597.
26. Noriega FR, Losonsky G, Lauderbaugh C, Liao FM, Wang JY, Levine MM. (1996) Engineered delta-guaB-A delta virG shigella-flexneri 2A strain CVD-1205 construction, safety, immunogenicity and potential efficacy. Infection and Immunity, 64, 3055-3061.
27. Treanor JJ, Reid Mattison H, Dumyati G, et al. (1992) Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Annals of Internal Medicine, 117, 625-633.
28. Bienenstock J, Johnson N, Perey DYE. (1973a) Bronchial lymphoid tissue. 1. Morphologic characteristics. Laboratory Investigation, 28, 686-692.
29. Bienenstock J, Johnson N, Perey DYE. (1973b) Bronchial lymphoid tissue. 2. Functional characteristics. Laboratory Investigation, 28, 693-698.
30. Bienenstock J. (1984) Bronchus-Associated Lymphoid Tissue. In: Bienenstock J, ed. Immunology of the Lung and Upper Respiratory Tract. McCraw-Hill Book Co, New York, 96-118.
31. Sminia T, van der Brugge-Gammelkoorn GJ, Juerissen S. (1989) Structure and function of the bronchus associated lymphoid tissue (BALT). Critical Review Immunology, 9, 119-150.
32. Pabst R. (1992) Is BALT a major component of the human lung immune system? Immunology Today, 13, 119-122.
33. O'Leary AD, Sweeney EC. (1986) Lymphoglandular complexes of the colon: structure and distribution. Histopathology, 10, 267-283.
34. Forrest BD, Shearman DJC, LaBrooy JT. (1990) Specific immune response in humans following rectal delivery of live typhoid vaccine. Vaccine, 8, 209-212.
35. Bergmann KC, Waldman RH. (1989) Oral immunization with influenza virus: experimental and clinical studies. In Mestecky, J, McGhee, JR, eds. New Strategies for Oral Immunization. Springer-Verlag, Berlin, Germany, 83-89.
36. Haneberg B, Kendall D, Amerongen HM, Apter FM, Kraehenbuhl JP, Neutra MR. (1994) Induction of specific immunoglobulin-A in the small-intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infection and Immunity, 62, 15-23.
37. Walker RI. (1994) New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine, 12, 387-400.
38. McGhee JR, Xuamano JC, Miller CJ, et al. (1994) The common mucosal immune-system - from basic principles to enteric vaccines with relevance for the female reproductive tract. Reproduction and Fertility Developments, 6, 369-379.
39. Neutra MR, Kraehenbuhl J-P. (1996) Antigen uptake by M cells for effective mucosal vaccines. In Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccines. Academic Press, London, 14-55.
40. Paar MB, Kepple L, Paar EL. (1991) Antigen recognition in the female reproductive tract. II. Endocytosis of horse radish peroxidase by langerhans cells in the murine vaginal epithelium. Biological Reproduction, 45, 261-265.
41. Miller CJ, McChesney M, Moore PF. (1992a) Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Laboratory Investigation, 67, 628-634.
42. Miller CJ, Vogel; P, Alexander NJ, Sutjipto S, Hendrickx AG, Marx PA. (1992b) Localization of SIV in the genital tract of chronically infected female rhesus macaques. American Journal of Pathology, 141, 653-660.
43. Parr ME, Parr EL. (1985) Immunohistochemical localization of immunoglugulins A, G and M in the mouse female genital tract. Journal of Reproductive Fertility, 74, 361-370.
44. Brandtzaeg P. (1989) Overview of the mucosal immune system. Current Topics in Microbiological Immunology, 146, 13-25.
45. Anderson DJ. (1996) The importance of mucosal immunology to problems in human reproduction. Journal of Reproductive Immunology, 31, 3-19.
46. Ada G, I. & Jones PD. (1986) The immune response to influenza infection. Current Topics in Microbiological Immunology, 123, 1-54.
47. Male D. (1986) Immunology: An Illustrated Outline. Churchill Livingstone, Edinburgh.
48. Mosmann TR, Coffman RL. (1987) Two types of mouse helper T-cell clone: implication for immune regulation. Immunology Today, 8, 223-227.
49. Coffman RL, Seymor BWP, Lebman DA, et al. (1988) The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunological Reviews, 102, 5-28.
50. Mosmann TR, Coffman RL. (1989) Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Immunology Today, 7, 145-173.
51. Waldman RH, Ganguly K. (1974) Immunity to infections on secretory surfaces. Journal of Infectious Disease, 130, 419-440.
52. Staats HF, McGhee JR. (1996) Application of basic principles of mucosal immunity to vaccine development. In Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccines. Academic Press, London, 17-39.
53. Eldridge JH, Hammond CJ, Muelbroek JA, Staas JK, Gilley RM, Tice TR. (1990) Controlled vaccine release in gut-associated lympgoid tissues. 1. Orally administered biodegradable microspheres target the Peyer's patches. Journal of Controlled Release, 11, 205-214.
54. Eldridge JH, Staas J, Meulbroek JA, McGhee JR, Tice TR, Gilley RM. (1991a) Biodegradable microspheres as a vaccine delivery system. Molecular Immunology, 28, 287-294.
55. Eldridge JH, Staas JK, Muelbroek JA, Tice TR, Gilley RM. (1991b) Biodegradable and biocompartible poly(DL-lactide-co-glycolide) microspheres as as adjuvant for staphylococcal enterotoxin B which enhances the level of toxin-neutralising antibodies. Infections and Immunity, 59, 2978-2985.
56. O'Hagan DT, McGhee JP, Holmgren J, et al. (1993b) Biodegradable microparticles for oral immunization. Vaccine, 11, 149-154.
57. Morris W, Steinhoff M, Russell P. (1994) Potential of polymer encapsulation technology for vaccine innovation. Vaccine, 12, 5-11.
58. Michalek SM, Eldridge JH, Curtiss, R III, Rosenthal KL. (1994) Antigen delivery systems: new approaches to mucosal immunization. In Ogra PL, Strober W, Mestecky J et al., eds. Handbook of Mucosal Immunology. Academic Press, London, 373-390.
59. Challacombe SJ, Rahman D, Jeffery H, Dayic SS, O'Hagan DT. (1992) Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigens. Immunology, 76, 164-168.
60. Reid R, Jarboe D, MoQueen C, et al. (1992) Microencapsulated pili promote cellular immune responses following enteric administration of vaccine. Vaccine, 10, 283.
61. Jones DH, Mcbride BW, Thornton C, Ohagan DT, Robinson A, Farrar GH. (1996) Orally-administered microencapsulated Bordetella-pertussis fimbriae protect mice from B. pertussis respiratory infection. Infectious Immunology, 64, 489-494.
62. Marx PA, Compans RW, Gettie A, et al. (1993) Protection against vaginal SIV2 transmission with microencapsulated vaccine. Science, 260, 1323-1327.
63. Moldoveanu Z, Novak M, Huang WQ, et al. (1993) Oral immunization with influenza virus in biodegradable microspheres. Journal of Infectious Disease, 167, 84-90.
64. Tacket CO, Reid RH, Buedeker EC, et al. (1994) Enteral immunization of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine, 12, 1270-1274.
65. Kiyono H, Miller C, Lu Y, et al. (1995) The common immune system for the reproductive tract: Basic principles applied towards an AIDS vaccine. Advances in Drug Delivery Reviews, 18, 23-51.
66. Jain SL, Barone KS, Flanagan MP, Michael JG. (1996) Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen. Vaccine, 14, 42-48.
67. Bowersock TL, Hogenesch H, Suckow M, Porter RE, Jackson R, Park H. (1996) Oral vaccination with alginate microsphere systems. Journal of Controlled Release, 39, 209-220.
68. Cox DS, Taubman MA. (1984) Oral induction of the secretory antibody response by soluble and particulate antigens. International Archives of Allergy and Applied Immunology, 75, 126-131.
69. O'Hagan DT, Palin KJ, Davis SS. (1989a) Poly (butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. Vaccine, 7, 213-216.
70. O'Hagan DT, Palin K, Davis SS, Artursson P, Sjoholm I. (1989b) Microparticles as potentially orally active immunological adjuvants. Vaccine, 7, 421-424.
71. Santiago NM, Ilstein S, Rivera T, et al. (1993) Oral immunization of rats with proteinoid microspheres encapsulating influenza virus antigens. Pharmaceutical Research, 10, 1243-1247.
72. Haas S, Miurafraboni J, Zavala F, Murata K, Leonebay A, Santiago N. (1996) Oral immunisation with a model protein entrapped in microspheres. Vaccine, 14, 785-791.
73. Heritage PL, Loomes LM, Jianxiong J, Brook MA, Underdown BJ. (1996) Novel polymer-grafted starch microparticles for mucosal delivery of vaccines. Immunology, 88, 162-168.
74. Almeida AJ, Alpar HO, Brown MRW. (1993) Immune-response to nasal delivery of antigenically intact tetanus toxoid associated with poly (1-lactic acid) microspheres in rats, rabbits and guinea-pigs. Journal of Pharmacy and Pharmacology, 45, 198-203.
75. Oka T, Honda T, Ohkuma K, Sakoh M, Nonka S. (1990) Influenza vaccine: enhancement of immune response by application of carboxy-vinylpolvmer. Vaccine, 8, 573-576.
76. O'Hagan DT, Rafferty D, Wharton S, Ilium L. (1993a) Intra vaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine, 11, 660-664.
77. Men Y, Thomasin C, Merkle HP, Gander B, Corradin G. (1995) A single dose administration of tetanus in biodegeadable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminium hydroxide. Vaccine, 13, 683-689.
78. Van Rooijen N. (1990) Liposomes as carrier and immunoadjuvant of vaccine antigens. In Miarahi A, ed. Bacterial Vaccines. Liss, A.R, New York, 255-279.
79. Alving CR. (1991) Liposomes as carriers of antigens and adjuvants. Journal of Immunological Methodology, 140, 1-13.
80. Gregory RL, Michalek SM, Richardson G, Harmon C, Hilton T, McGhee JR. (1986) Characterization of immune respone to oral administration of streptococcus sobrinus ribosomal preparations in liposomes. Infection and Immunity, 54, 780-786.
81. Klein JP, Wachsmann D, Scholler M. (1988) Liposomes as immunological adjuvants for Streptococcus mutans antigens. In Gergoriadis G, ed. Liposomes as Drug Carriers. Wiley, Chichester, 261-266.
82. Torchillin VP, Burkhanov SA, Mazhul LA, Ageeva ON. (1988) Liposomal vaccine against influenza virus. In Gregoriadis G, ed. Liposomes as Drug Curriers. J. Wiley & Sons, Chichester, 229-233.
83. El-Guink N, Kris RM, Goodman-Snitkoff G, Small PA, Mannino RJ. (1989) Intranasal immunization with protoliposomes protects against influenza. Vaccine, 7, 147-151.
84. Jackson S, Mestecky J, Childers NK, Michalek SM. (1990) Liposomes containing anti-idiotypic antibodies: an oral vaccine to induce protective secretory immune responses specific for pathogens of mucosal surfaces. Infection and Immunity, 58, 1932-36.
85. de Haan A, Geerligs HJ, Huchshorn JP, van Scharrenburg GJM, Palache AM, Wilschut J. (1945) Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine, 13, 155-162.
86. Pierce NF, Sacci JB. (1984) Enhanced mucosal priming by cholera toxin and procholeragenoid with lipoidal amine adjuvant (avridine) delivered in liposomes. Infection and Immunity, 44, 464-473.
87. Pierce NF, Sacci JB, Alving CR, Richardson EC. (1984) Enhancement by lipid A of mucosal immunogenicity of liposome-associated cholera toxin. Review Infectious Disease, 6, 5633-566.
88. Wachsmann D, Klein JP, Scholler M, Ogier J, Ackermans F, Frank KM. (1986) Serum and salivary antibody responses in rats orally immunized with Streptococcus mutans carbohydrate protein conjugate associated with liposomes. Infection and Immunity, 52, 408-413.
89. Michalek SM, Childers NK, Katz J, et al. (1989) Liposomes as oral adjuvants. Current Topics in Microbiological Immunology, 146, 51-58.
90. Ogawa T, Shimairchi H, Hamada S. (1989) Mucosal and systemic immune responses in BALB/c mice to Bacteroides gangivalis fimbriae administered orally. Infection and Immunity, 57, 3466-3471.
91. Zhou P, Kraehenbuhl JP, Neutra MR. (1995) Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes. Vaccine, 13, 637-644.
92. Curtiss R, III Kelly SM, Gulig PA, Nakayama K. (1989) Selective delivery on antigens by recombinant bacteria. Current Topics in Microbiological Immunology, 146, 35-49.
93. Doggett IA, Brown PK. (1996) Attenuated salmonella as vectors for oral immunization. In Kiyono H, Ogra PL, McGhee JK, eds. Mucosal Vaccines. Academic Press, London, 105-118.
94. McEwen J, Levi R, Horwitz RJ, Arnon R. (1992) Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in salmonella flagellin leads to partial protection in mice. Vaccine, 10, 405-144.
95. Arnon K, Levi R. (1995) Synthetic recombinant vaccines against viral agents. International Archives in Allergy and Immunology, 108, 321-326.
96. Kotloff KL, Herrington DA, Hale TL, et al. (1992) Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli k-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infection and Immunity, 60, 2218-2224.
97. Lagranderie M, Murray A, Gicquel B, Leclerc C, Gheorghiu M. (1993) Oral immunization with recombinant BCG induces cellular and humoral immune responses against foreign antigen. Vaccine, 11, 1283-1240.
98. Linde K, Randhagen B, Beer J, et al. (1993) Shigella flexneri 2a and sonni 1 vaccine with two attenuating markers: constraction, tolerability and immunogenicity in 143 children aged 3-7 years. Vaccine, 11, 197-200.
99. Barzu S, Fontaine A, Eanaonetti P, Phalipon A. (1996) Induction of a local anti-IpaC antibody response in mice by use of a shigella-flexneri 2A vaccine canditate - implications for use of IpaC. Infection and Immunity, 64, 1190-1196.
100. Sory M, Hermand P, Vaerman J, Cornelis GR. (1990) Oral immunization of mice with a live recombinant Yersinia enterocolitica, 0, 9 strain that produces the cholera toxin B subunit. Infectious Immunology, 58, 2420-2428.
101. Pouwels PH, Leer RJ, Boersma WJA. (1996) The potential of lactobacillus as a carrier fir oral immuimization: development and preliminary characterization of vector systems for targeting delivery of antigens. Journal of Biotechnology, 44, 183-192.
102. Hone DM, Wu SG, Powell RJ, et al. (1996) Optimization of live oral salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune-responses. Journal of Biotechnology, 44, 203-207.
103. Jagusztyn-Krynicka EK, Clark-c, urtiss JE, Curtiss R. (1993) Eschericha coli heat-labile toxin subunit B fusions with Streptcoccus sobrinus antigens expressed by Salmonella typhimuium oral vaccine strains: importance of the linker for antigenicity and biological activities of the hybrid proteins. Infectious Immunology, 61, 1004-1015.
104. Valentine PJ, Meyer K, Rivera MM, et al. (1996) Induction of SIV capsid-specific CTL and mucosal slgA in mice immunized with a recombinant salmonella-typhimurium aroa mutant. Vaccine, 14, 138-146.
105. Gonin P, Oualikene VV, Fournier A, Eliot M. (1996) Comparison of the efficacy of replication- defective adenovirus and Nyvac poxvirus as vaccine vectors in mice. Vaccine, 14, 1083-1087.
106. Morin JE, Lubeck MD, Barton JH, Conley AJ, Davis AR, Hung PP. (1987) Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in heimsters. Proceedings of the National Academy of Science USA, 84, 4626-4630.
107. Lubeck MD, Davis AR, Chengalvala M, et al. (1989) Immunpgenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proceedings of the National Academy of Science USA, 86, 6763-6767.
108. Prevec L, Schbeider M, Rosenthal KL, Belbeck L, et al. (1989) Use of human adenovirus-based vectors for antigen expression in animals. Journal of General Virology, 70, 429-434.
109. Lubeck MD, Davis AR, Chengalvala M, et al. (1990) Immunization of chimpanzees against hepatitis B using live recombinant adenovirus-hepatitis vaccine, In: Coutsaget P, Tong MJ, eds. Pregress in Hepatitis B Immunization. John Libbey Eurotext Ltd, London, 51-57.
110. Both GW, Lockett LJ, Janardhana V, et al. (1993) Protective immunity to rotavirus-induced diarrhoea is passively transferred to new-born mice from native dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. Virology, 193, 940-950.
111. Gallichan WS, Johnson DC, Graham FL, Rosenthal KL. (1993) Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. Journal of Infectious Disease, 168, 622-629.
112. Lubeck MD, Natuk RJ, Chengalvala M, et al. (1994) Immunogenicity of recombinant adenovirus-human immunodeficiency virus-vaccines in chimpanzees following intranasal administration. Aids Research and Human Retroviruses, 10, 1443-1449.
113. Rosenthal KL, Copelang KFT, Gallichan WS. (1996) Recombinant adenoviruses as vectors for mucosal immunity. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccines. Academic Press, London, 147-158.
114. Stott EJ, Ball LA, Young KK, Furze J, Wertz GW. (1986) Human respiratory synctial virus glycoprotein G expressed from a recombonant vaccinia virus vector protects mice against live-virus challenge. Journal of Virology, 60, 607-613.
115. Kanesaki T, Murphy BR, Collins PL, Ogra PL. (1991) Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus. Journal of Virology, 65, 657-663.
116. Kundig TM, kalberer CP, Hengartner H, Zinkernagel RM. (1993) Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine, 11, 1154-1158.
117. Ramsay AJ, Leong K-H, Boyle D, Ruby J, Ramshaw IA. (1994) Enhancement of mucosal IgA responses by interleukins 5 and 6 encoded in recombinant vaccine-vectors. Reproductive Fertility Development, 6, 389-392.
118. Kenny JS, Hughes BW, Masda MP, Allison AC. (1989) Influence of adjuvants of the quantity, affinity, isotype and epitope specificity of murine antibodies, Journal of Immunological Methodology, 121, 157-166.
119. Elson CO, Dertzbaugh MT. (1994) Mucosal Adjuvants. In: Ogra PL, ed. Handbook of Mucosal Imnninology. Academic Press, London, 391-402.
120. Warren HS, Vogel FR, Chedid LA. (1986) Current status of immunological adjuvants. Annual Review of Immunology, 4, 369-399.
121. Gregoriadis G. (1990) Immunological adjuvants: a role for liposomes. Immunology Today, 11, 89-97.
122. Woodard LF. (1990) Surface chemistry and classification of vaccine adjuvants and vehicles. In: Liss AR, ed. Bacterial Vaccines. Liss, A.R. Inc, 281-306.
123. Lycke N, Holmgren J. (1986) Strong adjuvant proterties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology, 59, 301-308.
124. Clements JD, Hartxog NM, Lynon FL. (1988) Adjuvant activity of Escherichia coli heat labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine, 6, 269-277.
125. Mekalanos JJ, Collier RJ, Romig WR. (1979) Enzymatic activity of cholera toxin. II. Relationships to proteolytic processing, disulphide bond reduction, and subunit composition, Journal of Biological Chemistry, 254, 5855-5861.
126. Snider DP. (1995) The mucosal adjuvant activities of ADP-Ribosylating bacterial enterotoxins. Critical Review of Immunology, 15, 317-348.
127. Nugent J. (1996) Design and Delivery of Non-parenteral Vaccines. Queen's University of Belfast, Belfast, U.K.
128. Elson CO, Ealding W. (1984) Generalised systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. Journal of Immunology, 132, 2736-2741.
129. Wilson AD, Stokes CR, Bourne FJ. (1989) Adjuvant effect of cholera toxin on the mucosal immune response to soluble proteins. Scandinavian Journal of Immunology, 29, 739-745.
130. Jackson RJ, Fujihashi K, Xuamano JC, Kiyono H, Elson CO, Mcghee JR. (1993) Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody-responses to tetanus toxoid by use of cholera-toxin as an adjuvant. Infection and Immunity, 61, 4272-1279.
131. Vajdy M, Lycke NH. (1992) Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology, 75, 488-492.
132. Vajdy M, Lycke N. (1993) Stimulation of antigen-specific T-cell and B-cell memory in local as well as systemic lymphoid-tissues following oral immunization with cholera-toxin adjuvant. Immunology, 80, 197-203.
133. Tamura S-I, Ito Y, Asanukma H, et al (1992) Cross protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. Journal of Immunology, 146, 981-988.
134. Walsh EE. (1993) Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine, 11, 1135-1138.
135. Tamura SI, Ishihara K, Miyata K, Aizawa C, Kurata T. (1995) Mechanism of enhancement of the immune-responses to influenza vaccine with cholera-toxin B-subunit and a trace amount of holotoxin. Vaccine, 13, 339-341.
136. Hannant D, Easeman RL, Mumford JA. (1996) Mucosal vaccination with inactivated equine influenza virus stimulates neutralising antibody in that nasopharynx of horses. Veterinary Immunology and Immunopathology, 54, 205-209.
137. Tamura S, Asanuma H, Ito Y, et al. (1994a) Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice. Vaccine, 12, 310-316.
138. Thapar MA, Parr EL, Parr MB. (1990) The effect of adjuvants on antibody titres in mouse vaginal fluid after intravaginal immunization. Journal of Reproductive Immunology, 17, 207-216.
139. Hordnes K, Digranes A, Hangen IL, et al. (1995) Systemic and mucosal antibody-responses to group-B streptococci following immunization of the colonic-rectal mucosa. Journal of Reproductive Immunology, 28, 247-262.
140. Oien NL, Brideau RJ, Walsh EE, Wathen MW. (1994) Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera-toxin b- subunit. Vaccine, 12, 731-735.
141. Takada A, Shimizu Y, Kida H. (1994) Protection of mice against aujeszkys-disease virus-infection by intranasal vaccination with inactivated virus. Journal of Veterinary Medical Science, 56, 633-637.
142. Walsh EE. (1994) Humoral, mucosal, and cellular immune-response to topical immunization with a subunit respiratory syncytial virus-vaccine. Journal of Infectious Disease, 170, 345-350.
143. Tamura S, Yamanaka A, Shimohara M, et al. (1994b) Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine, 12, 419-426.
144. Muller CP, Beauverger P, Schneider F, Jung G, Brons NHC. (1995) Cholera-toxin-b stimulates systemic neutralizing antibodies after intranasal co-immunization with measles-virus. Journal of General Virology, 76, 1371-1380.
145. Takada A, Kida H. (1995) Induction of protective antibody-responses against pseudorabies virus by intranasal vaccination with glycoprotein-B in mice. Archives of Virology, 140, 1629-1635.
146. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM. (1996) Salivary, nasal, genital, and systemic antibody-responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera-toxin b-subunit. Infection and Immunity, 64, 1272-1283.
147. Asanuma H, Koide F, Suzuki Y, et al. (1995) Cross-protection against influenza-virus infection in mice vaccinated by combined nasal subcutaneous administration. Vaccine, 12, 3-5.
148. Czerkinsey C, Russell MW, Lycke N, Lindbald M, Holmgren J. (1989) Oral administration of a streptococcal antigen coulped to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infection and Immunity, 57, 1072-1077.
149. Pierre P, Denis O, Bazin H, Mbella EM, Vaerman J-P. (1992) Modulation of oral tolerance to ovalbumin by cholera toxin and its B subunit. European Journal of Immunology, 22, 3179-3182.
150. Chen KS, Strober W. (1990) Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response. European Journal of Immunology, 20, 433-436.
151. Wilson AD, Clarke CJ, Stokes CR. (1990) Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scandinavian Journal of Immunology, 31, 443-451.
152. Menge AC, Michalek SM, Russell MW, Mestecky J. (1993) Immune-response of the female rat genital-tract after oral and local immunization with keyhole limpet hemocyanin conjugated to the cholera toxin-b subunit. Infection and Immunity, 61, 2162-2171.
153. Vadolas J, Davies JK, Wright PJ, Strugnell RA. (1995) Intranasal immunization with liposomes induces strong mucosal immune responses in mice. European Journal of Immunology, 25, 969-975.
154. Dertzbaugh MT, Elson CO. (1993) Comparative effectiveness of the cholera toxin-b subunit and alkaline-phosphatase as carriers for oral vaccines. Infectious Immunology, 61, 48-55.
155. Pavlovskis OR, Rollwagen FM, Rollins DM, Walker RI. (1992) Experimental oral camplyobacter vacine. Vaccine, 10, 290.
156. Rollwagen FM, Pacheco ND, Clements JD, Pavlovskis O, Rollins DM, walker RI. (1993) Killed campylobacter elicits immune-response and protection when administered with an oral adjuvant. Vaccine, 11, 1316-1320.
157. Tsuji T, Inoue T, Miyama A, Okamoto K, Honda T, Miwatani T. (1990) A single amino acid substution in the A subunit of Escherichia coli enterotoxin results in a loss of toxic activity. Journal of Biological Chemistry, 265, 22520-22525.
158. Lycke N, Tsuji T, Holmgren J. (1992) The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. European Journal of Immunology, 22, 2277-2281.
159. Dickson BL, Clements JD. (1996) Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccines. Academic Press, London, 73-87.
160. Wilson AD, Robinson A, Irons L, Stokes CR. (1993) Adjuvant action of cholera- toxin and pertussis toxin in the induction of IgA antibody-response to orally-administered antigen. Vaccine, 11, 113-118.
161. Aitken R, Hirst TR. (1993) Recombinant enterotoxins as vaccines against Escherichia coli-mediated diarrhoea. Vaccine, 11, 227-233.
162. Nashar TO, Amin T, Marcello A, Hirst TR. (1993) Current progress in the development of the b-subunits of cholera-toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes. Vaccine, 11, 235-240.
163. Lipscombe M, Charles IG, Roberts M, Dougan G, Tite J, Fairweather NF. (1991) Intranasal immunization using the B subunit of Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertusis P.69 antigen. Molecular Microbiology, 5, 1385-1392.
164. Hazama M, Mayumi-Aono A, Miyazaki T, Hinuma S, Fujisawa Y. (1993) Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotien D fused with immunomodulating proteins, and B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology, 78, 643-649.
165. Elson CO, Tomasi M, Chang T-T, Jobling MG, Holmes RK. (1995) Immunogenicity and adjuvanticity of mutant cholera toxin (CT) molecules. FASEB Journal, 9, A290.
166. Holmgren J, Lycke N, Czerkinsky C. (1993) Choleratoxin and cholera-b subunit as oral mucosal adjuvant and antigen vector systems. Vaccine, (1993), 1179-1184.
167. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. (1984) Iscom, a novel structute for antigenic presentation of membrane proteins from enveloped viruses. Nature, 308, 547-160.
168. Morein B. (1988) The iscom antigen-presenting system. Nature, 332, 287-288.
169. Morein B. (1990) Iscoms. Veterinary Microbiology, 23, 79-84.
170. Morein B, Lovgren K, Hoglund S. (1989) Immunostimulating Complex (ISCOM). In: Gregoriadis G, Allison AC, Poste G, eds. Immunological Adjuvants and Vaccines. Plenum Press, London, 153-161.
171. Mowat AM, Donachie AM, Reid G, Jarrett O. (1991) Immune-stimulating complexes containing Quil A and protein antigen prime class 1 MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology, 72, 317-322.
172. Mowat AM, Maloy KJ, Donachie AM. (1993) Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology, 80, 527-534.
173. Lovgren K. (1988) The serum antibody response distributed in subclass and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scandinavian Journal of Immunology, 27, 241-245.
174. Jones PD, Tha Hla R, Morein B, Lovgren K, Ada GL. (1988) Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in miscelles and immunostimulatory complexes (Iscoms). Scandinavian Journal of Immunology, 27, 645-652.
175. Lovgren K, Kaberg H, Morein B. (1990) An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clinical and Experimental Immunology, 82, 435-439.
176. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. (1990) Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature, 344, 873-875.
177. Thapar MA, Parr EL, Parr MB. (1991) Secretory immune responses in mouse vaginal fluid after pelvis, parenteral, or vaginal immunization. Immunology, 70, 121-125.
178. Maloy KJ, Donachie AM, Mowat AM. (1995) Induction of Th1 and Th2 cd4 (+) T-cell responses by oral or parental immunization with iscoms. European Journal of Immunology, 25, 2835-2841.
179. Heeg K, Kuon W, Wagner H. (1991) Vaccination of class I major histocompatibility complex (MHC) restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. European Journal of Immunology, 21, 1523-1527.
180. Trudel M, Nadon F, Seguin C, Brault S, Lusignan Y, Lemieux S. (1992) Initiation of cytotoxic T-cell response and protection of Balb/c mice with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine, 10, 107-112.
181. Steineker F, Kersten G, van Bloois L, et al. (1995) Comparison of 24 different adjuvants for inactivated HIV-2-split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulation. Vaccine, 13, 45-53.
182. Kensil CR, Parel U, Lennick M, Marciani D. (1991) Separation and characterizarion of saponins with adjuvant activity from Quillaja saponaria molina cortex. Journal of Immunology, 146, 431-437.
183. Livingston PO, Adiuri S, Heliing F, et al. (1994) Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine, 12, 1275-1280.
184. Oka T, Honda T, Morokuma R, Ginnaga A, Ohkuma K, Sakoh M. (1994) Enhancing effects of pertusus toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally. Vaccine, 12, 1255-1258.
185. Michalek SM, Morisaki I, Gregory RL, Kiyono H, Hamada S, McGhee JR. (1983) Oral adjuvants enhance IgA responses to Streptococcus mutans. Molecular Immunology, 20, 1009-1018.
186. Morisaki I, Michalek SM, Harmon CC, Terii M, Hamada S, McGhee JR. (1983) Effective immunity to dental caries: enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants. Infection and Immunity, 40, 577-591.
187. Butler JE, Richardson HB, Swanson PA, Kopp WC, Suelzer MT. (1983) The influence of muramyl peptide on the secretory immune response. Annals of the New York Academy of Science, 409, 669-687.
188. Ogra P, Leibovitz E, Zhao-Ri G. (1989) Oral Immunization and secretory immunity to Viruses. Current Topics in Microbial Immunology, 146, 73-81.
189. Fukushima A, Too YC, Toshimatsu K, Matsuzawa K, Tamura M, Tomooka S. (1996) Effect of MDP-LYS (L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus. Vaccine, 14, 485-491.
190. Bergmann KC, Waldman RH. (1988) Enhanced murine respiratory tract IgA antibody response to oral influenza vaccine when combined with lipoidal amine. International Archives of Allergy and Applied Immunology, 87, 334-335.
191. Peppard JV, Mann RV, Montgomery PC. (1988) Antibody reproduction in rats following ocular-topical or gastrointestinal immunisation. Kinetics of local and systemic antibody production. Current Eye Research, 7, 471-481.
192. O'Hagan DT, Rafferty D, McKeating JA, Illum E. (1992) Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. Journal of General Virology, 73, 2141-2145.
193. Tomasi M, Hearn TL. (1996) ISCOMs, liposomes and oil-based vaccine delivery systems. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccines. Academic Press, London, 175-186.
194. Flo J, Goldman H, Roux M, Massouh E. (1996) Oral administration of a bacterial immunomodulator enhances the immune response to cholera toxin. Vaccine, 14, 1167-1173.
195. Erdile EF, Guy B. (1997) OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant. Vaccine, 15, 988-995.
196. Keller D, Koster FT, Marks DH, Hosbach P, Erdile LF, Mays JP. (1994) Safety and immunogenicity of a recombinant outer surface protein A lyume vaccine. Journal of the American Medical Association, 271, 1764-1768.
197. Van Hoecke C, Comberbach M, Degrave D. (1996) Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. Vaccine, 14, 1621-1626.
198. Ben Ahmeida ETS, Gregoriadis G, Potter CW, Jennings R. (1993) Immunopotentiation of local and systemic humoral responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine, 11, 1302-1309.
199. Harag-Mahmod FI, Wyde PR, Rosborough JP, Six HR. (1988) Immunogenicity and efficacy of orally administered inactivated influenza virus vaccine in mice. Vaccine, 6, 262-268.
200. Mestecky J, McGhee JR. (1989) Oral immunization: past and present. Current Topics in Microbiological Immunology, 146, 3-11.
201. Hirabayashi Y, Kurata H, Funato H, et al. (1990) Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine, 8, 243-248.
202. Abraham E. (1992) Intranasal immunisation with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response. Vaccine, 10, 461-468.
203. Reuman PD, Keely SP, Schiff GM. (1990) Rapid recovery in mice after combined nasal/oral immunisation with killed respiratory syncytial virus. Journal of Medical Virology, 32, 67-72.
204. Wassen L, Schon K, Holmgren H, Jertborn M, Lycke N. (1996) Local intravaginal vaccination of the female genital tract. Scandinavian Journal of Immunology, 44, 408-414.
205. Parr EL, Parr MB, Thapar M. (1988) A comparison of specific antibody responses in mouse vaginal fluid after immunisation by several routes. Journal of Reproductive Immunology, 14, 165-176.
206. Parr EL, Parr NB. (1990) A comparison of antibody titres in mouse uterine fluid after immunisation by several routes, and the effect of the uterus on antibody titres in vaginal fluid. Journal of Reproductive Fertility, 89, 619-625.
207. Hordnes K, Tynning T, Kvam AI, Jonsson R, Haneberg B. (1996) Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant women. Infection and Immunity, 64, 1643-1652.
208. Lehner T, Bergmeier LA, Panagiotidi C, et al. (1992) Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science, 258, 1365-1369.
209. Lehner T, Bergmeier LA, Tao C, et al. (1994) Targeted lymph node immunization with simian immuno-deficiency virus p27 antigen to elicit genital, rectal and urinary immune response in non-human primates. Journal of Immunology, 153, 1858-1868.
210. Klavinskis LS, Bergmeier LA, Gao L, et al. (1996) Mucosal or targeted lymph node immunization of masques with a particulate SIVp27 protein elicits vrius-specific CTL in the genito-rectal mucosa and draining lymph nodes. Journal of Immunology, 157, 2521-2527.
211. McLean CS, Ní Challanáin D, Duncan I, Boursnell MEG, Jennings R, Inglis SC. (1996) Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine, 14, 987-992.
212. Wahren B. (1996) Gene vaccines. Immunotechnology, 2, 77-83.
213. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro C, Robinson HL. (1993) DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proceedings of the National Academy of Science USA, 90, 11478-11482.
214. Robinson HL, Hunt LA, Webster RG. (1993) Protection against a lethal influenza virus challenge by immunization with a haemaglutinin-expressing plasmid DNA. Vaccine, 11, 957-960.
215. Martinon F, Krishnan S, Lenzen G, et al. (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. European Journal of Immunology, 23, 1719-1722.
216. Logan JJ, Bebok Z, Walker LC, et al. (1995) Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium. Gene Therapy, 2, 38-49.